Novartis AG (NVS)

84.51
0.31 0.37
NYSE : Health Care
Prev Close 84.20
Open 84.62
Day Low/High 84.49 / 84.66
52 Wk Low/High 66.93 / 86.90
Volume 141.77K
Avg Volume 2.14M
Exchange NYSE
Shares Outstanding 2.34B
Market Cap 197.48B
EPS 2.80
P/E Ratio 29.89
Div & Yield 2.72 (3.20%)

Latest News

European Stocks Drift Lower; Dollar Slumps Further After Healthcare Bill Collapse

European Stocks Drift Lower; Dollar Slumps Further After Healthcare Bill Collapse

European stocks are firmly on the back foot.

Novartis Tops Q2 Earnings Estimate, Boosts Alcon Full Year Sales Guidance

Novartis Tops Q2 Earnings Estimate, Boosts Alcon Full Year Sales Guidance

Novartis sees stronger full-year Alcon sales

Netflix, Microsoft Better Blow Everyone Away With Their Earnings This Week, Or Else

Netflix, Microsoft Better Blow Everyone Away With Their Earnings This Week, Or Else

The second-quarter earnings season picks up speed.

Valeant Suffers Another Blow After the Approval of Johnson & Johnson's Psoriasis Treatment

Valeant Suffers Another Blow After the Approval of Johnson & Johnson's Psoriasis Treatment

The approval of Johnson & Johnson's psoriasis treatment will have an adverse impact on Valeant in the second half of 2017, Wells Fargo argued.

Dow Scores Record Close as Retail Roars Higher, Walmart Rallies

Dow Scores Record Close as Retail Roars Higher, Walmart Rallies

Upbeat guidance from Target inspires retail rally.

Dow on Track for Record Close as Retail Roars Higher, Walmart Rallies

Dow on Track for Record Close as Retail Roars Higher, Walmart Rallies

Upbeat guidance from Target inspires retail rally.

Healthcare Stocks Sell Off, Retail Rallies on Upbeat Guidance From Target

Healthcare Stocks Sell Off, Retail Rallies on Upbeat Guidance From Target

Upbeat guidance from Target inspires retail rally.

Novartis Passes FDA Blood Cancer Panel 'With Flying Colors,' Gives Positive Read Through For Others

Novartis Passes FDA Blood Cancer Panel 'With Flying Colors,' Gives Positive Read Through For Others

The company received a thumbs up from an FDA advisory committee for its CAR-T therapy to treat leukemia in children and young adults.

Novartis Secures FDA Panel's Approval for Cutting Edge Cancer Drug

Novartis Secures FDA Panel's Approval for Cutting Edge Cancer Drug

The panel voted 10-0 that the drug, tisagenlecleucel, should be approved to treat patients with relapsed B-cell acute lymphoblastic leukemia (ALL), the most common form of U.S. childhood cancer.

Landmark Novartis Immunotherapy Faces Crucial FDA Hearing Wednesday

Landmark Novartis Immunotherapy Faces Crucial FDA Hearing Wednesday

FDA advisory committee poised to make recommendation regarding CAR T therapy from Novartis that represents the first possibility of treatment calling on the body's own engineered cells to attack cancer.

FDA Decision on Novartis Gene Therapy Drug Could Benefit Kite Pharma

FDA Decision on Novartis Gene Therapy Drug Could Benefit Kite Pharma

Investment firm Canaccord Genuity believes Kite Pharma is poised to take advantage of the positive results from Novartis' experimental gene therapy drug.

Stocks Lower as Tech Losses Escalate, Senate Delays Its Healthcare Plan

Stocks Lower as Tech Losses Escalate, Senate Delays Its Healthcare Plan

Tech, healthcare slide weighs on rest of markets.

Senate Punts Vote on Healthcare Bill, Wall Street Fares Poorly

Senate Punts Vote on Healthcare Bill, Wall Street Fares Poorly

Healthcare's slide weighs on rest of markets.

Healthcare Stock Rally Can't Save S&P 500 From Another Bad Day

Healthcare Stock Rally Can't Save S&P 500 From Another Bad Day

Healthcare leads markets after the release of the Senate health plan.

Nasdaq Leads Wall Street, Healthcare Stocks Rise on Senate Bill

Nasdaq Leads Wall Street, Healthcare Stocks Rise on Senate Bill

Healthcare leads markets after the release of the Senate health plan.

Healthcare Leads as Stocks Turn Higher After Release of Senate Bill

Healthcare Leads as Stocks Turn Higher After Release of Senate Bill

Healthcare leads markets after Senate bill's release.

Stock Futures Dip as Crude Oil Looks to Correct Days-Long Slide

Stock Futures Dip as Crude Oil Looks to Correct Days-Long Slide

Futures lower even as crude oil rises.

Novartis Shares Lead Swiss Market Higher After CANTOS Trial Success

Novartis Shares Lead Swiss Market Higher After CANTOS Trial Success

Novartis shares led gainers in Switzerland Thursday after the pharmaceuticals group told investors that its Canakinumab drug met its primary endpoint in phase three clinical trials.

FDA Commissioner Takes on Big Pharma

FDA Commissioner Takes on Big Pharma

Investors should watch these companies come July 18th.

The More Things Change…

… and market internals are seeing some changes.

Regeneron Soars After Eye Drug Competitor Novartis Releases Positive Data

Regeneron Soars After Eye Drug Competitor Novartis Releases Positive Data

Novartis released data from its RTH258 clinical trials illustrating that RTH258 does not need to be injected as often as Regeneron's rival drug, Eylea.

Novartis Secures European Approval For Biosimilar Cancer Treatment Rixathon

Novartis Secures European Approval For Biosimilar Cancer Treatment Rixathon

Novartis said Monday that it has received EC approval for a blood cancer treatment known as Rixathon, a biosimilar version of Roche's Rituxan that generated $7.5 billion in 2016 sales.

Google and Novartis Back Medicxi's New $300 Million Fund

Google and Novartis Back Medicxi's New $300 Million Fund

Developing a promising drug? This new investment fund is looking to invest in Phase 2 candidates.

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Generic drugmakers are likely to limit themselves to acquisitions of small- and mid-sized companies in the immediate future because of over-leveraging and turmoil in the executive ranks..

The Reasons Kite Pharma Is Set to Fly Higher

The Reasons Kite Pharma Is Set to Fly Higher

BTIG analyst Dane Leone noted three key reasons why he executed today's upgrade of the stock.

Bristol Myers, Novartis to Explore Potential Treatment for Metastatic Colorectal Cancer

Bristol Myers, Novartis to Explore Potential Treatment for Metastatic Colorectal Cancer

Bristol-Myers will conduct the study and both companies will evaluate the findings.